THE PHARMACEUTICAL SECTOR AND PARALLEL TRADE

2019 ◽  
pp. 405-430
Author(s):  
Edurne Navarro Varona
Keyword(s):  
Parallel Trade ◽  
Pharmaceutical Sector

scholarly journals LYGIAGREČIOS PREKYBOS RIBOJIMO FARMACIJOS SEKTORIUJE VERTINIMAS

Teisė ◽  
2013 ◽  
Vol 86 ◽  
pp. 144-159
Author(s):  
D. Miniotas
Keyword(s):  
Pharmaceutical Industry ◽  
Market Integration ◽  
Negative Attitude ◽  
Competition Law ◽  
Internal Market ◽  
Vertical Restraints ◽  
Legal Environment ◽  
Parallel Trade ◽  
Pharmaceutical Sector

Straipsnyje nagrinėjamas vienas iš „sunkiųjų“ vertikaliųjų apribojimų konkurencijos teisėje – lygiagrečios prekybos draudimas (ribojimas), koncentruojantis į tokio pobūdžio susitarimų vertinimą farmacijos sektoriaus kontekste. Straipsnyje atskleidžiama, kad dėl specifinės ekonominės ir teisinės farmacijos sektoriaus aplinkos lygiagrečios prekybos ribojimo susitarimai ne visada turėtų būti laikomi antikonkurenciniais. Diskutuojama, kiek yra pagrįsta, kad tokio pobūdžio susitarimų itin neigiamas vertinimas yra labiau nulemtas Europos Sąjungos vidaus rinkos integracijos tikslo nei teisinės ar ekonominės logikos.Te article examines one of the hardcore vertical restraints in competition law – prohibition (restriction) of parallel trade, with the focus on the assessment of such agreements within the context of pharmaceutical industry. The article discloses that due to the very specific economical and legal environment of the pharmaceutical sector, agreements restricting parallel trade should not be condemned as anticompetitive in all cases. It is discussed whether it is reasonable that extremely negative attitude towards such agreements is more conditioned upon the European Union’s internal market integration goal than legal or economic logic.

Pharmacist for a Healthy India – Swasth Bharath

2016 ◽  
Vol 9 (2) ◽  
pp. 3151-3154
Author(s):  
G. N. Singh
Keyword(s):  
Pharmaceutical Industry ◽  
Research And Development ◽  
Healthcare System ◽  
Scientific Knowledge ◽  
Health Sector ◽  
High Technology ◽  
Pharmaceutical Sector ◽  
The Public ◽  
Pharmacy Council ◽  
Global Player

India has emerged as a global player for pharmaceuticals. The pharmaceutical revolution of 1970-90 of Indian Pharma Industry had demonstrated that India could be self-sufficient in the manufacture of essential drugs at affordable prices. The turnover of Indian Pharmaceutical is over $30 billion in 2015 including $15 billion in exports.  It was a great honor to preside the 67th Indian pharmaceutical congress held in Mysore. The topic of Pharmacists for a Healthy India is close to my heart and being a regulator myself, I feel that the Pharmacy fraternity can play a much larger role in contributing to the healthcare system in India. Pharmacist as such are involved in a big way in the regulation of drugs, be it manufacture, be it sale or research and development. A contribution of the Pharmacists is there at every stage till the drug reaches the consumer safely. For this purpose, the society needs a pool of well qualified and experienced pharmacists, which requires regular updating of their knowledge to keep pace with the developments taking place in the pharmaceutical sector. The advancements in technology and the emerging challenges in the health sector require pharmacists to shoulder the responsibilities towards the utilization of scientific knowledge in the use of modern medicines and the protection of the public against dangers of wrong use of drugs. The Pharmacy Council of India on its part will have to ensure that the courses offered for creating a high technology based are calibrated in such a way that the education and skills developed suit to the requirements of the Pharmaceutical Industry as well as needs to the patients

scholarly journals The Impact of Dynamic Capabilities on Sustainable Competitive Advantage in the Pharmaceutical Sector in Egypt

2017 ◽  
Vol 6 (2) ◽  
pp. 1
Author(s):  
Albert Naiem Naguib ◽  
Eahab Elsaid ◽  
Abdel Moneim Elsaid
Keyword(s):  
Competitive Advantage ◽  
Dynamic Capabilities ◽  
Secondary Data ◽  
Primary Data ◽  
Sustainable Competitive Advantage ◽  
Firm Characteristics ◽  
Pharmaceutical Sector ◽  
Chi Square ◽  
Pharmaceutical Firms ◽  
The Impact

This study examines the relationship between dynamic capabilities (experience, routine, skills, firm characteristics, knowledge and technology) and competitive advantage sustainability in the Egyptian pharmaceutical sector. The data was collected using primary and secondary data sources. Primary data was collected from questionnaires distributed to 160 top managers in 20 pharmaceutical firms. The secondary data about pharmaceutical firms like rankings, revenues and market share was collected from external sources such as Intercontinental Marketing Service (IMS). The questionnaires examine six independent variables based on a five-scale Likert scale. The methodology used in the study is non-probability sampling (judgmental sampling), Cronbach’s alpha reliability coefficient and Chi-square tests. The results support the notion that there is a significant relationship between four of the six dynamic capabilities (experience, skills, firm characteristics and knowledge) and the competitive advantage sustainability for pharmaceutical firms in Egypt. Designing the questionnaire and formulating the questions to target the required field was challenging, given that the topic is dynamic and the business scene in Egypt has witnessed drastic political changes since January 2011. The study should assist pharmaceutical companies in Egypt in directing their investments properly and in determining the weaknesses in their dynamic capabilities that need to be addressed.

scholarly journals The Impact of Mergers and Acquisitions and Sustainability on Company Performance in the Pharmaceutical Sector

2021 ◽  
Vol 13 (12) ◽  
pp. 6525
Author(s):  
Diana Marieta Mihaiu ◽  
Radu-Alexandru Șerban ◽  
Alin Opreana ◽  
Mihai Țichindelean ◽  
Vasile Brătian ◽  
...  
Keyword(s):  
Stock Market ◽  
Mergers And Acquisitions ◽  
Performance Improvement ◽  
Score Function ◽  
Pharmaceutical Companies ◽  
Company Performance ◽  
Direct Impact ◽  
Pharmaceutical Sector ◽  
Financial Measures ◽  
The Impact

The primary goal of this study was to determine the impact of mergers and acquisitions (M&A) and the environmental, social, and governance (ESG) sustainability scores of companies. In this regard, efforts to measure and analyze the evolution of a company’s performance, taking into account financial and non-financial measures using a score function, are adapted to the pharmaceutical sector. The sample consisted of 100 leading pharmaceutical companies, ranked by stock market capitalization, who registered 30% (n = 492) of the total M&A transactions over the study period (2010–2020). There was a direct and positive link between the M&A process and the evolution of company performance. The ESG score, as an indicator for measuring sustainability, has a positive and direct impact on company performance, indicating that a high ESG score determines an increase in company performance. A similar impact is identified for companies involved in M&A processes, meaning that companies in the pharmaceutical sector tend to register a performance improvement.

Industry Watch

2004 ◽  
Vol 08 (06) ◽  
pp. 297-308
Keyword(s):  
Phase Ii ◽  
Cancer Vaccine ◽  
Phase Ii Trial ◽  
Invasive Cancer ◽  
Pharmaceutical Sector ◽  
Regional Office ◽  
New Approach ◽  
Bird Flu ◽  
Non Invasive ◽  
Anti Cancer

Ai Scientific Awarded R&D Start Grant. CSIRO Drug Effective against Bird Flu. AustCancer Commences Anti-cancer Vaccine Phase II Trial. New Approach against Cancer. Non-invasive Cancer Test. China’s Chemical Pharmaceutical Sector Q1 2003 Performance. International Generic Companies Target India’s Manufacture Infrastructure. Cardinal Health Sets up Regional Office in Singapore. BRV Enters Agreement with Genedata.

Sign in / Sign up

Export Citation Format

Share Document